Adial Pharmaceuticals, Inc. (AZR) company profile
Price, market cap and P/E appear here once daily prices are connected.
About Adial Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for the treatment or prevention of addiction and related disorders. Its primary investigational drug candidate is AD04, a therapeutic agent designed to treat alcohol use disorder (AUD). The company develops this treatment alongside a companion diagnostic genetic test to identify and target patients with specific genotypes. Adial has no approved products and focuses its resources on research, development, and clinical evaluation.
The company operates in the United States and has conducted clinical investigations across six European countries, including Sweden, Finland, Poland, Latvia, Bulgaria, and Croatia. It also pursues strategic partnerships to support potential commercialization in Europe. Adial maintains its principal executive offices in Glen Allen, Virginia.
Summary of the business section of Adial Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Adial Pharmaceuticals, Inc.
- Headquarters
- Charlottesville, VA
- Address
- 1180 Seminole Trail, Suite 495 22901
- Phone
- (434) 422-9800
- Website
- adial.com
- Employees
- 6, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- CBIZ CPAs P.C, Marlton, New Jersey
Stock & identifiers
- Ticker
- AZR
- Other tickers
- ADIL
- Exchange
- Nasdaq
- IPO date
- Jul 30, 2018
- Shares outstanding
- 3M, Aug 12, 2026
- Public float
- $6.48M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-25 reverse, Feb 6, 2026; 1-for-25 reverse, Aug 7, 2023
- SEC CIK
- 1513525
- CUSIP
- 00688A304
- ISIN
- US00688A3041
- EIN
- 80-0667150
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Matt Davidson | Chief Development Officer, Director | 302,841 |
| Tony Goodman | Chief Operating Officer, Director | 26,523 |
| Cary J. Claiborne | Chief Executive Officer, Director | 40,417 |
| Vinay Shah | Chief Financial Officer | 17,325 |
| Wendy B. Young | Director | – |
| J. Kermit Anderson | Director | – |
| Kevin Schuyler | Director | 9,447 |
| Robertson H. Gilliland | Director | 104,609 |
| James W. Newman Jr. | Director | 338,463 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $890.65K | $600.17K | $464.41K | $4 | – |
| FY2024 | $976.34K | $823.53K | $352.31K | $19 | – |
| FY2023 | $801.62K | $575.60K | $412.02K | $35 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Cary Claiborne Chief Executive Officer and Member of the Board of Directors | $489.25K | $244.63K | $80.54K | $76.24K | $890.65K | -26% |
| Vinay Shah Chief Financial Officer (7) | $315.00K | $94.50K | $5.25K | $44.10K | $458.86K | +403% |
| Tony Goodman Chief Operating Officer | $300.00K | $67.81K | $54.86K | $47.30K | $469.97K | +25% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jul 30, 2018
- Offer price
- $5.00
- Securities offered
- 1,464,000
- Gross proceeds
- $7.32M
- Exchange
- Nasdaq
- First trading day
- Jul 27, 2018
- First-day close
- $4.05-19.0%
- Lock-up ends (est.)
- Jan 23, 2019
“The initial public offering price of each unit will be $5.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“Form 10-K, we have six employees, of which five are full-time employees, and one is a consultant.”
Corporate history
Events identified from SEC filings